Sponsor pipeline

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany clinical trial pipeline

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

First posted	Trial	Phase	Status
2026-09-30	NCT07850635 A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated…	Phase 1	Not Yet Recruiting

NCT ID	Title	Condition	Status	Updated
Phase 4
NCT07176689	Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)	Desmoid Tumor	Recruiting	2026-10-13
Phase 2
NCT03962543	MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1…	Plexiform Neurofibroma	Active, Not Recruiting	2026-10-06
NCT07170644	A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis…	Desmoid Tumor	Active, Not Recruiting	2026-09-15
Phase 1
NCT06997276	Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib	Healthy	Recruiting	2026-10-14
NCT06251310	SW-682 in Advanced Solid Tumors	Advanced Solid Tumor	Recruiting	2026-10-02
NCT07850635	A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated…	Neurofibromatosis Type 1-Associated Plexiform Neurofibromas	Not Yet Recruiting	2026-09-30

Get alerts when SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.